Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

J&J must pay $4 million in punitive damages in latest asbestos cancer trial

Published 05/24/2018, 03:23 PM
Updated 05/24/2018, 03:23 PM
© Reuters. A Johnson & Johnson building is shown in Irvine, California

By Tina Bellon

(Reuters) - A California jury on Thursday ordered Johnson & Johnson (NYSE:JNJ) to pay $4 million in punitive damages to a woman who said she developed cancer after being exposed to asbestos in the company's baby powder, pushing the total damages award in the case to $25.7 million.

The decision in Los Angeles Superior Court comes on top of $21.7 million in compensatory damages that the same jury awarded to the woman and her husband on Wednesday.

Joanne Anderson, 68, was diagnosed with mesothelioma, a form of cancer closely linked to asbestos exposure. The case marked the second trial loss for J&J over similar allegations.

J&J has denied that its talc products contain asbestos or cause cancer, citing decades of testing by independent laboratories and scientists. But plaintiffs claim asbestos and talc, which are closely linked minerals, are intermingled in the mining process, making it impossible to remove the carcinogenic substance.

Of Wednesday's $21.7 million in compensatory damages, J&J was assigned 67 percent of the liability, Anderson's lawyer, Chris Panatier, said.

In addition to J&J, Anderson and her husband last year sued a unit of Imerys SA, Cyprus Amax Minerals, a unit of Brenntag, Honeywell International (NYSE:HON) and other talc suppliers. It was not immediately clear whether any companies besides J&J were subject to the verdict.

The Imerys unit, Imerys Talc America, was previously dismissed from the lawsuit, a spokesman said.

Panatier on Thursday did not immediately respond to a request for comment.

J&J in a statement said it was disappointed with the decision and would begin the appeals process. "We will continue to defend the safety of our product because it does not contain asbestos or cause mesothelioma," the company said.

J&J is battling some 9,000 cases claiming its talc products cause ovarian cancer, but the talc litigants have recently focused on claims based on alleged asbestos contamination.

A New Jersey state court jury in April ordered J&J and Imerys Talc America to pay $117 million to a man who alleged he developed mesothelioma due to asbestos exposure from J&J Baby Powder.

© Reuters. A Johnson & Johnson building is shown in Irvine, California

An appeal is pending.

A California jury in November last year cleared J&J of liability in another mesothelioma lawsuit.

The company and Imerys' U.S. unit, as well as a unit of U.S. drugstore chain Rite Aid, are also facing another mesothelioma trial in a South Carolina court.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.